Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elicio TherapeuticsELTX -1.30%26 3-1 Month Momentum % is -68.89% as of Aug. 23, 2026. GuruFocus rates ELTX with a GF Score™ of 26/100. Among 1,386 Biotechnology companies, Elicio Therapeutics ranks worse than 98.85% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-23), Elicio Therapeutics's 3-1 Month Momentum % is -68.89%.
The industry rank for Elicio Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
ELTX's 3-1 Month Momentum % is ranked worse than 98.85% of 1386
companies
in the Biotechnology industry
Industry Median: -7.29
vs ELTX: -68.89
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Elicio Therapeutics 3-1 Month Momentum % Related Terms
ELTX vs TELO, INO, ALPS: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Elicio Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (ELTX) has a 3-1 Month Momentum % of -68.89% as of Aug. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Elicio Therapeutics and its competitors. According to the industry distribution chart, Elicio Therapeutics ranks #1370 out of 1386 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Elicio Therapeutics' 3-1 Month Momentum % too high?
Elicio Therapeutics' current 3-1 Month Momentum % is -68.89%. Based on the distribution chart, Elicio Therapeutics ranks #1370 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicio Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' 3-1 Month Momentum % compare to TELO and INO?
According to the Biotechnology industry distribution chart, Elicio Therapeutics ranks #1370 out of 1386 companies for 3-1 Month Momentum %. This places Elicio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current 3-1 Month Momentum % is -68.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current 3-1 Month Momentum % of -68.89%. The current 3-1 Month Momentum % is -68.89%. Elicio Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current 3-1 Month Momentum % is -68.89% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
26GF Score
Get the complete analysis for ELTX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTX has been successfully added to your 
